A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.

ABSTRACT:

Aims

RPR 102681, a cholecystokinin-B antagonist, increased dopamine (DA) release and reduced cocaine self-administration in animals. This pilot study sought to assess the safety and pharmacokinetics (PK) of co-administration of RPR 102681 and cocaine, and to confirm the DA release mechanism of RPR 102681.

Methods

Sixteen cocaine-dependent participants were randomized to either placebo or RPR102681 at 3 ascending doses; cocaine was co-administered at steady state of RPR 102681. [¹¹ C]raclopride positron emission tomography scans were conducted at baseline and at each RPR102681 dose.

Results

RPR 102681 was well tolerated, and safe to co-administer with cocaine. RPR 102681 did not alter the PK of either cocaine or its metabolite benzoylecgonine and showed no i

SUBMITTER: Elkashef A 

PROVIDER: S-EPMC6309275 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature